12 documents found, page 1 of 2
The potential of the fibronectin inhibitor Arg-Gly-Asp-Ser in the development o...
Castro-Ribeiro, Maria L.; Castro, Vânia Isabel Baptista; Castro, Joana vieira de; Pires, R. A.; Reis, R. L.; Costa, Bruno M.; Ferreira, HelenaGlioblastoma (GBM) is the most lethal and common malignant primary brain tumor in adults. An important feature that supports GBM aggressiveness is the unique composition of its extracellular matrix (ECM). Particularly, fibronectin plays an important role in cancer cell adhesion, differentiation, proliferation, and chemoresistance. Thus, herein, a hydrogel with mechanical properties compatible with the brain and...
MCT1 is a new prognostic biomarker and its therapeutic inhibition boosts respon...
Miranda-Gonçalves, Vera; Gonçalves, Celine Saraiva; Granja, Sara Costa; Castro, Joana Isabel Martins Cosme Vieira; Reis, Rui M.; Costa, Bruno M.<i>Background:</i> Glioblastomas (GBMs) present remarkable metabolism reprograming, in which many cells display the “Warburg effect”, with the production of high levels of lactate that are extruded to the tumour microenvironment by monocarboxylate transporters (MCTs). We described previously that MCT1 is up-regulated in human GBM samples, and MCT1 inhibition decreases glioma cell viability and aggressiveness. I...
Fucoidan/chitosan nanoparticles functionalized with anti-ErbB-2 target breast c...
Oliveira, Catarina; Gonçalves, Céline S.; Martins, Eduarda P.; Neves, N. M.; Reis, R. L.; Costa, Bruno M.; Silva, Tiago H.; Martins, AlbinoThe work herein presented reports the development of fucoidan/chitosan nanoparticles (NPs) loaded with gemcitabine and functionalized with ErbB-2 antibody at their surface (NPs + Gem + Ab). The maximum immobilization of ErbB-2 on NPs' surface was set at 10 mu g mL(-1) and resulted in NPs with a size around 160 nm, a polydispersity index of 0.18, and a zeta potential of 21 mV. ErbB-2 is overexpressed in some sub...
Adenosine inhibits cell proliferation differently in human astrocytes and in gl...
Marcelino, Helena; Carvalho, Tiago M. A.; Tomás, Joana; Teles, Francisca I.; Honório, Ana C.; Rosa, Carolina B.; Costa, Ana R.; Costa, Bruno M.Glioblastoma (GBM) is the most common brain primary tumour. Hypoxic regions in GBM are associated to tumour growth. Adenosine accumulates in hypoxic regions and can affect cell proliferation and survival. However, how proliferating GBM cells respond/adapt to increased adenosine levels compared to human astrocytes (HA) is not clarified and was addressed in the present work. GBM cell lines and HA were treated for...
Large expert-curated database for benchmarking document similarity detection in...
Brown, Peter; Tan, Aik-Choon; El-Esawi, Mohamed A.; Liehr, Thomas; Blanck, Oliver; Gladue, Douglas P.; Almeida, Gabriel M. F.; Cernava, TomislavMade available in DSpace on 2020-12-11T01:57:28Z (GMT). No. of bitstreams: 0 Previous issue date: 2019-10-29; Griffith University Gowonda HPC Cluster; Queensland Cyber Infrastructure Foundation; Document recommendation systems for locating relevant literature have mostly relied on methods developed a decade ago. This is largely due to the lack of a large offline gold-standard benchmark of relevant documents tha...
Glioblastoma: is there any blood biomarker with true clinical relevance?
Linhares, Paulo; Carvalho, Bruno; Vaz, Rui; Costa, Bruno M.Glioblastoma (GBM) is the most frequent malignant primary brain tumor in adults, characterized by a highly aggressive, inflammatory and angiogenic phenotype. It is a remarkably heterogeneous tumor at several levels, including histopathologically, radiographically and genetically. The 2016 update of the WHO Classification of Tumours of the Central Nervous System highlighted molecular parameters as paramount feat...
A novel molecular link between HOXA9 and WNT6 in glioblastoma identifies a subg...
Gonçalves, Céline S.; Xavier‐Magalhães, Ana; Martins, Eduarda P.; Pinto, Afonso A.; Pires, Manuel; Pinheiro, Célia; Reis, Rui M.; Sousa, NunoDespite much effort to improve treatments, patients with malignant glioma still present a very poor prognosis that has not changed significantly in the last decades. In this context, it is crucial to better understand glioma pathogenesis to identify new molecular prognostic subgroups and therapeutic targets. WNT6 was recently identified as a new oncogenic molecule in glioblastoma (GBM), with prognostic value in...
The long non-coding RNA HOTAIR is transcriptionally activated by HOXA9 and is a...
Xavier-Magalhães, Ana; Gonçalves, Céline S; Fogli, Anne; Lourenço, Tatiana; Pojo, Marta; Pereira, Bruno; Rocha, Miguel; Lopes, Maria CelesteThe lncRNA HOTAIR has been implicated in several human cancers. Here, we evaluated the molecular alterations and upstream regulatory mechanisms of HOTAIR in glioma, the most common primary brain tumors, and its clinical relevance. HOTAIR gene expression, methylation, copy-number and prognostic value were investigated in human gliomas integrating data from online datasets and our cohorts. High levels of HOTAIR w...
Crosstalk between glial and glioblastoma cells triggers the "go-or-grow" phenot...
Oliveira, Ana Isabel; Anjo, Sandra I.; Vieira de Castro, Joana; Serra, Sofia C.; Salgado, António J.; Manadas, Bruno; Costa, Bruno M.Background: Glioblastoma (GBM), the most malignant primary brain tumor, leads to poor and unpredictable clinical outcomes. Recent studies showed the tumor microenvironment has a critical role in regulating tumor growth by establishing a complex network of interactions with tumor cells. In this context, we investigated how GBM cells modulate resident glial cells, particularly their paracrine activity, and how th...
Impact of mesenchymal stem cells' secretome on glioblastoma pathophysiology
Vieira de Castro, Joana; Gomes, Eduardo D.; Granja, Sara; Anjo, Sandra I.; Baltazar, Fátima; Manadas, Bruno; Salgado, António J.; Costa, Bruno M.Background: Glioblastoma (GBM) is a highly aggressive primary brain cancer, for which curative therapies are not available. An emerging therapeutic approach suggested to have potential to target malignant gliomas has been based on the use of multipotent mesenchymal stem cells (MSCs), either unmodified or engineered to deliver anticancer therapeutic agents, as these cells present an intrinsic capacity to migrate...